¼¼°èÀÇ RNA ÆíÁý ±â¼ú ½ÃÀå : RNA À¯Çüº°, ±â¼úº°, ¿ëµµº°, ±¹°¡º°, Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À² ¿¹Ãø(2024-2032³â)
RNA Editing Technologies Market, By Type of RNA, By Technique, By Application, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
»óǰÄÚµå : 1515375
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2024³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 375 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,520,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,467,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 7,858,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

º¸°í¼­ ÇÏÀ̶óÀÌÆ®

RNA ÆíÁý ±â¼ú ½ÃÀå ±Ô¸ð´Â 2023³â¿¡ 2¾ï 6,543¸¸ ´Þ·¯·Î 2024³âºÎÅÍ 2032³â±îÁö ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR) 6.8%·Î È®´ë

RNA ÆíÁý ±â¼ú ½ÃÀå - ½ÃÀå ¿ªÇÐ

RNA Ä¡·áÁ¦ÀÇ ÀÓ»ó ÆÄÀÌÇÁ¶óÀÎ È®´ë°¡ ½ÃÀå ¼ö¿ä¸¦ ÃËÁø

RNA Ä¡·áÁ¦ ºÐ¾ß´Â RNA ÆíÁý ±â¼úÀÇ Áøº¸¿¡ °ßÀεǾî ÃÖ±Ù ¸î ³â°£ »ó´çÇÑ ¼ºÀåÀ» ÀÌ·ç°í ÀÖ½À´Ï´Ù. mRNA ¹é½Å, RNA °£¼·(RNAi) Ä¡·áÁ¦, RNA ÆíÁý Ä¡·áÁ¦¸¦ Æ÷ÇÔÇÑ RNA ±â¹Ý Ä¡·áÁ¦´Â ¾Ï°ú À¯Àü¼º Áúȯ¿¡¼­ °¨¿°°ú ½Å°æ Áúȯ¿¡ À̸£±â±îÁö ±¤¹üÀ§ÇÑ Áúº´ Ä¡·á¿¡ Å« ÀáÀç·ÂÀ» º¸ÀÔ´Ï´Ù. RNA ÆíÁý ±â¼úÀº Áúº´À» ÀÏÀ¸Å°´Â µ¹¿¬º¯À̸¦ ¼öÁ¤Çϰí À¯ÀüÀÚ ¹ßÇöÀ» Á¶ÀýÇϱâ À§ÇØ RNA ¼­¿­¿¡ Á¤È®ÇÑ ¼öÁ¤À» Ãß°¡ ÇÒ ¼ö ÀÖÀ¸¸ç RNA Ä¡·áÁ¦ °³¹ß¿¡ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ÀÔ´Ï´Ù. mRNA ¹é½ÅÀÇ ¼º°ø°ú RNA »ý¹°Çп¡ ´ëÇÑ ÀÌÇØ°¡ ³ô¾ÆÁü¿¡ µû¶ó RNA Ä¡·áÁ¦ÀÇ ÀÓ»ó ÆÄÀÌÇÁ¶óÀÎÀÌ È®´ëµÊ¿¡ µû¶ó RNA ÆíÁý ±â¼ú¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ô¾ÆÁú °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. CRISPR(Clustered Regularly Interspaced Short Palindromic Repeats) ±â¼úÀº RNA ÆíÁý¿¡ ÆÐ·¯´ÙÀÓ À̵¿À» °¡Á®¿À°í RNA ¼­¿­À» Á¤È®ÇÏ°Ô º¯°æÇÏ´Â ´É·ÂÀ» Å©°Ô Çâ»ó ½ÃÄ×½À´Ï´Ù. RNA ÆíÁý ºÐ¾ßÀÇ Áøº¸¿¡ µû¶ó ÇöÀç CRISPR ±â¹Ý RNA ÆíÁý Ç÷§ÆûÀÇ °³¼±°ú °­È­¿¡ ÃÊÁ¡À» ¸ÂÃá ¿¬±¸°¡ °è¼ÓµÇ°í ÀÖ½À´Ï´Ù. RNA ºÐÀÚÀÇ ¼¼Æ÷ ³»¿¡¼­ È¿À²ÀûÀ̰í Á¤È®ÇÑ Å¸°ÙÆÃÀ» º¸ÀåÇϱâ À§ÇØ Àü´Þ ¸ÞÄ¿´ÏÁòÀ» ÃÖÀûÈ­ÇÏ´Â °ÍÀÌ ¸ñÇ¥ÀÔ´Ï´Ù. ¿¬±¸ÀÚµéÀº ¶ÇÇÑ CRISPR ±â¹Ý RNA ÆíÁýÀÇ Å¸°ÙÆÃ ´É·Â°ú ¹ü¿ë¼ºÀ» °­È­ÇÔÀ¸·Î½á ±× ¹üÀ§¸¦ È®´ëÇϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °³¹ßÀº ƯÈ÷ À¯Àü¼º Áúȯ°ú °¨¿°¿¡ ´ëÇÑ ¹Ì·¡ÀÇ Ä¡·áÀû °³ÀÔ¿¡ Å« ±â´ë¸¦ °®°Ô ÇÕ´Ï´Ù. CRISPR ±â¹Ý RNA ÆíÁý ±â¼úÀÇ Á¤È®¼º°ú ÀûÀÀ¼º Çâ»óÀº »õ·Î¿î Ä¡·á Àü·«À¸·Î À̾îÁö°í Áö±Ý±îÁö Ä¡·áÇÒ ¼ö ¾ø¾ú´ø »óÅÂÀÇ È¯ÀÚ¿¡°Ô Èñ¸ÁÀ» °¡Á®¿Ã °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

RNA ÆíÁý ±â¼ú ½ÃÀå - ÁÖ¿ä ÀλçÀÌÆ®

´ç»çÀÇ ¸®¼­Ä¡ ¾Ö³Î¸®½ºÆ®°¡ °øÀ¯ÇÑ ºÐ¼®¿¡ µû¸£¸é ¼¼°è ½ÃÀåÀº ¿¹Ãø ±â°£(2024-2032³â)¿¡ ¾à 6.8%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¸Å³â ¼ºÀåÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.

RNA À¯Çüº° ºÎ¹®¿¡¼­ ¸Þ½ÅÀú RNA(mRNA) º¯ÇüÀº 2023³â¿¡ ÃÖ´ë ½ÃÀå Á¡À¯À²À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¿ëµµº°·Î´Â 2023³â¿¡ ¾ÏÀÌ ÁÖ¿ä À¯ÇüÀ̾ú½À´Ï´Ù.

Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2023³â ÁÖ¿ä ¼öÀÍ¿øÀ̾ú½À´Ï´Ù.

RNA ÆíÁý ±â¼ú ½ÃÀå - ¼¼ºÐÈ­ ºÐ¼® :

¼¼°èÀÇ RNA ÆíÁý ±â¼ú ½ÃÀåÀº RNAÀÇ À¯Çü, ±â¼ú, ¿ëµµ, Áö¿ª¿¡ µû¶ó ±¸ºÐµË´Ï´Ù.

½ÃÀåÀº RNAÀÇ À¯Çü¿¡ µû¶ó ¼¼ °¡Áö ¹üÁÖ·Î ³ª´¹´Ï´Ù. ¸Þ½ÅÀú RNA º¯Çü, Æ®·£½ºÆÛ RNA º¯Çü, ¸®º¸¼Ø RNA º¯ÇüÀÔ´Ï´Ù. ÇöÀç RNA ÆíÁý ±â¼ú ½ÃÀå¿¡¼­´Â ¸Þ½ÅÀú RNA(mRNA) º¯ÇüÀÌ ÁÖ¿ä ºÎ¹®ÀÌ µÇ°í ÀÖ½À´Ï´Ù. mRNA´Â À¯Àü Á¤º¸¸¦ DNA¿¡¼­ ¸®º¸¼ØÀ¸·Î Àü´ÞÇÏ¿© ´Ü¹éÁú·Î ¹ø¿ªÇÔÀ¸·Î½á À¯ÀüÀÚ ¹ßÇö¿¡ ÇʼöÀûÀÔ´Ï´Ù. ¸Þƿȭ ¹× ¾Æµ¥³ë½Å Å»¾Æ¹Ì³ëÈ­¿Í °°Àº RNA·ÎÀÇ º¯ÇüÀº mRNAÀÇ ¾ÈÁ¤¼º, ½ºÇöóÀ̽Ì, ±¹¼ÒÈ­, ¹ø¿ª È¿À²À» Á¶ÀýÇÏ¿© ¼¼Æ÷ °úÁ¤ ¹× À¯ÀüÀÚ ¹ßÇö ¿ªÇп¡ ¿µÇâÀ» ¹ÌĨ´Ï´Ù.

½ÃÀåÀº ¿ëµµ¿¡ µû¶ó ¼¼ °¡Áö ¹üÁÖ·Î ³ª´¹´Ï´Ù. ¾Ï, À¯ÀüÀÚ Áúȯ, ÀϽÃÀûÀÎ Áúº´ÀÔ´Ï´Ù. ¿ëµµº°·Î ¾ÏÀº ¼¼°è RNA ÆíÁý ±â¼ú ½ÃÀåÀÇ ÁÖ¿ä ºÎ¹®ÀÔ´Ï´Ù. ¾ÏÀÇ ±¤¹üÀ§ÇÏ°í º¹ÀâÇÑ ¼ºÁúÀº ¹ß¾ÏÀÇ ºÐÀÚ ±âÀüÀ» ÀÌÇØÇϰí Çõ½ÅÀûÀÎ Ä¡·á Àü·«À» °³¹ßÇϱâ À§ÇÑ ±¤¹üÀ§ÇÑ Á¶»ç ³ë·ÂÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. RNA ÆíÁý ±â¼úÀº Á¾¾çÀÇ ¼ºÀå, ÀüÀÌ, Ä¡·á ÀúÇ×¼º°ú °ü·ÃµÈ ºñÁ¤»óÀûÀÎ RNA ºÐÀÚ¸¦ Ç¥ÀûÀ¸·Î ÇÔÀ¸·Î½á ¾Ï Ä¡·á¿¡¼­ Á¤¹ÐÀÇ·á¿¡ À¯¸ÁÇÑ ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù.

RNA ÆíÁý ±â¼ú ½ÃÀå - Áö¸®Àû ÅëÂû

Áö¿ªÀûÀ¸·Î ÀÌ ½ÃÀåÀº ºÏ¹Ì, ¶óƾ¾Æ¸Þ¸®Ä«, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«¿¡ °ÉÃÄ ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀÇ °í°´ ±¹°¡´Â ½ÃÀåÀ» ´õ¿í ¼¼ºÐÈ­ÇÕ´Ï´Ù. ºÏ¹Ì´Â ¼¼°è RNA ÆíÁý ±â¼ú ½ÃÀåÀÇ ÁÖ¿ä Áö¿ªÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ÀÌÁ¡Àº RNA ÆíÁý ±â¼úÀÇ ÃÖÀü¼±¿¡ ÀÖ´Â À¯¸íÇÑ Çмú ±â°ü, »ý¸í °øÇÐ ±âÁö, Á¦¾à ȸ»ç°¡ Áö¿øÇÏ´Â °ß°íÇÑ R&D ÀÎÇÁ¶ó µî ¿©·¯ ¿äÀÎ ¶§¹®ÀÔ´Ï´Ù. ±âŸ ƯÀüÀ¸·Î ºÏ¹Ì´Â Á¤ºÎ±â°ü, ¹Î°£Àç´Ü, º¥Ã³Ä³ÇÇÅ» ±â¾÷À¸·ÎºÎÅÍ ÀÚ±ÝÀ» ¹Þ°í ÀÇ·á ¹× »ý¸í°øÇÐ ¿¬±¸¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÅõÀÚ´Â ½Å±Ô RNA ÆíÁý ±â¼úÀÇ °³¹ß, ¿¬±¸ÀÇ ÀÓ»ó ÀÀ¿ë¿¡ÀÇ Àü°³, RNA ÆíÁý¿¡ ±Ù°ÅÇÑ Ä¡·á¹ý ¹× Áø´Ü¹ýÀÇ »ó¾÷È­¸¦ ÃËÁøÇÕ´Ï´Ù.

RNA ÆíÁý ±â¼ú ½ÃÀå - °æÀï ±¸µµ :

RNA ÆíÁý ±â¼ú °æÀï ±¸µµ¿¡¼­ ±â¾÷Àº °æÀï·Â°ú ½ÃÀå ¿ìÀ§¸¦ À¯ÁöÇϱâ À§ÇÑ Àü·«Àû ¼ö´ÜÀ» °³¹ßÇϰí ÀÖ½À´Ï´Ù. ²÷ÀÓ¾ø´Â ±â¼ú Çõ½ÅÀº CRISPR ±â¹Ý ½Ã½ºÅÛ°ú ±âº» ÆíÁý ±â¼úÀ» Æ÷ÇÔÇÑ »õ·Î¿î ÆíÁý µµ±¸ÀÇ °³¹ßÀ» ÃßÁøÇÏ¿© RNA º¯ÇüÀÇ Á¤È®¼º°ú È¿À²¼ºÀ» Çâ»ó½Ãŵ´Ï´Ù. Çмú±â°ü°ú »ý¸í°øÇбâ¾÷°úÀÇ °øµ¿¿¬±¸´Â ÃÖ÷´Ü ¿¬±¸¿¡ ´ëÇÑ Á¢±ÙÀ» ¿ëÀÌÇÏ°Ô ÇÏ°í ±â¼ú·ÂÀ» È®´ëÇÕ´Ï´Ù. ±ÔÁ¦ Áؼö¸¦ Áß½ÃÇÔÀ¸·Î½á ǰÁú ±âÁØ Áؼö¸¦ º¸ÀåÇϰí ÀÌÇØ°ü°èÀÚ ¹× ±ÔÁ¦±â°üÀÇ ½Å·Ú¸¦ Á¶¼ºÇÕ´Ï´Ù. °ß°íÇÑ ÁöÀû Àç»ê Æ÷Æ®Æú¸®¿À´Â µ¶ÀÚÀûÀÎ ±â¼úÀ» º¸È£ÇÏ°í °æÀï·ÂÀ» Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, ½ÃÀå¿¡ Àû±ØÀûÀ¸·Î Âü¿©ÇÏ°í °í°´¿¡ ¸Â´Â Áö¿ø ¼­ºñ½º°¡ °í°´ ¸¸Á·µµ¸¦ ³ôÀ̰í RNA ÆíÁý ¼Ö·ç¼Ç ½ÃÀå ¸®´õ½ÊÀ» °­È­Çϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå RNA ÆíÁý ±â¼ú ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå RNA ÆíÁý ±â¼úÀÇ ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå RNA ÆíÁý ±â¼ú »ê¾÷ Á¶»ç

Á¦5Àå RNA ÆíÁý ±â¼ú ½ÃÀå : COVID-19ÀÇ ¿µÇ⠺м®

Á¦6Àå RNA ÆíÁý ±â¼ú ½ÃÀå »óȲ

Á¦7Àå RNA ÆíÁý ±â¼ú ½ÃÀå-RNA À¯Çüº°

Á¦8Àå RNA ÆíÁý ±â¼ú ½ÃÀå - ±â¼úº°

Á¦9Àå RNA ÆíÁý ±â¼ú ½ÃÀå- ¿ëµµº°

Á¦10Àå RNA ÆíÁý ±â¼ú ½ÃÀå-Áö¿ªº°

Á¦11Àå ÁÖ¿ä º¥´õ ºÐ¼®-RNA ÆíÁý ±â¼ú ¾÷°è

Á¦12Àå ¾Ö³Î¸®½ºÆ®ÀÇ Àü¹æÀ§ Àü¸Á

JHS
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

RNA Editing Technologies Market size was valued at USD 265.43 Million in 2023, expanding at a CAGR of 6.8% from 2024 to 2032.

The field of Global RNA Editing includes a wide range of innovative tools and techniques specifically developed to modify RNA molecules for therapeutic, research, and diagnostic purposes. These RNA editing technologies facilitate targeted changes to RNA sequences, providing unique opportunities to correct genetic mutations, regulate gene expression, and create new RNA-based therapies.

RNA Editing Technologies Market- Market Dynamics

Expanding clinical pipeline of RNA therapeutics to propel market demand

The field of RNA therapeutics has experienced substantial growth in recent years, driven by advancements in RNA editing technologies. RNA-based therapeutics, including mRNA vaccines, RNA interference (RNAi) therapeutics, and RNA editing therapies, show great potential for the treatment of a wide range of diseases, from cancer and genetic disorders to infectious diseases and neurological conditions. RNA editing technologies are crucial in developing RNA therapeutics by enabling precise modifications to RNA sequences to correct disease-causing mutations or modulate gene expression. As the clinical pipeline of RNA therapeutics expands, fueled by the success of mRNA vaccines and the increasing understanding of RNA biology, the demand for RNA editing technologies is expected to rise. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology has brought about a paradigm shift in RNA editing, significantly enhancing our ability to precisely modify RNA sequences. As the RNA editing field advances, ongoing research is focused on refining and enhancing CRISPR-based RNA editing platforms. Efforts are aimed at optimizing delivery mechanisms to ensure efficient and accurate targeting of RNA molecules within cells. Researchers are also working to expand the scope of CRISPR-based RNA editing by enhancing its targeting capabilities and versatility. These developments hold significant promise for future therapeutic interventions, especially for genetic disorders and infectious diseases. The increased precision and adaptability of CRISPR-based RNA editing technologies are expected to lead to novel therapeutic strategies, offering hope for patients with previously untreatable conditions.

RNA Editing Technologies Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 6.8% over the forecast period (2024-2032)

Based on Type of RNA segmentation, Messenger RNA (mRNA) modification was predicted to show maximum market share in the year 2023

Based on Application segmentation, cancer was the leading type in 2023

Based on region, North America was the leading revenue generator in 2023

RNA Editing Technologies Market- Segmentation Analysis:

The Global RNA Editing Technologies Market is segmented based on Type of RNA, Technique, Application, and Region.

The market is divided into three categories based on Type of RNA: Messenger RNA Modification, Transfer RNA Modification and Ribosomal RNA Modification. Currently, Messenger RNA (mRNA) modification is the leading segment in the RNA Editing Technologies Market. mRNA is essential for gene expression by transferring genetic information from DNA to ribosomes, where it is translated into proteins. Modifications to RNA, such as methylation and adenosine deamination, regulate mRNA stability, splicing, localization, and translation efficiency, thereby influencing cellular processes and gene expression dynamics.

The market is divided into three categories based on Application: Cancer, Genetic Disorders and Temporary Maladies. In terms of application, cancer is the predominant segment in the Global RNA Editing Technologies Market. The widespread and intricate nature of cancer has driven extensive research efforts to understand the molecular mechanisms of oncogenesis and develop innovative therapeutic strategies. RNA editing technologies present promising opportunities for precision medicine in cancer treatment by targeting abnormal RNA molecules associated with tumor growth, metastasis, and therapy resistance.

RNA Editing Technologies Market- Geographical Insights

In terms of geography, this market spans North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. Customer nations within these regions further segment the market. North America is the leading region in the Global RNA Editing Technologies Market. This dominance is due to several factors, including a robust research and development infrastructure supported by renowned academic institutions, biotechnology hubs, and pharmaceutical companies that are at the forefront of RNA editing technologies. Additionally, North America benefits from substantial investments in healthcare and biotechnology research, funded by government agencies, private foundations, and venture capital firms. These investments drive the development of novel RNA editing technologies, the translation of research into clinical applications, and the commercialization of RNA editing-based therapies and diagnostics.

RNA Editing Technologies Market- Competitive Landscape:

In the landscape of RNA Editing Technologies, companies deploy strategic measures to maintain competitiveness and market dominance. Continuous innovation drives the development of novel editing tools, including CRISPR-based systems and base editing technologies, enhancing precision and efficiency in RNA modification. Collaborations with academic institutions and biotech firms facilitate access to cutting-edge research and expand technological capabilities. Emphasis on regulatory compliance ensures adherence to quality standards, fostering trust among stakeholders and regulatory bodies. Robust intellectual property portfolios safeguard proprietary technologies, providing a competitive edge. Furthermore, proactive market outreach and tailored customer support services bolster client satisfaction, reinforcing market leadership in RNA editing solutions.

Recent Developments:

In September 2023, Wave Life Sciences applied for a clinical trial of its RNA editing candidate, WVE-006. Upon approval, dosing for the trial began in the U.K. This milestone represents the first instance of an RNA editing candidate advancing to clinical trials, marking a significant achievement in the field.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL RNA EDITING TECHNOLOGIES MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHT

ProQR Therapeutics NV

Sirna Therapeutics, Inc.

Shape Therapeutics, Inc.

Korro Bio, Inc.

Beam Therapeutics, Inc.

QIAGEN N.V.

UniQure NV (UniQure)

LAVA Therapeutics N.V.

argenx SE

Arrowhead Pharmaceuticals, Inc.

Others

GLOBAL RNA EDITING TECHNOLOGIES MARKET, BY TYPE OF RNA - MARKET ANALYSIS, 2019 - 2032

GLOBAL RNA EDITING TECHNOLOGIES MARKET, BY TECHNIQUE- MARKET ANALYSIS, 2019 - 2032

GLOBAL RNA EDITING TECHNOLOGIES MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

GLOBAL RNA EDITING TECHNOLOGIES MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

Table of Contents

1. RNA Editing Technologies Market Overview

2. Executive Summary

3. RNA Editing Technologies Key Market Trends

4. RNA Editing Technologies Industry Study

5. RNA Editing Technologies Market: COVID-19 Impact Analysis

6. RNA Editing Technologies Market Landscape

7. RNA Editing Technologies Market - By Type of RNA

8. RNA Editing Technologies Market - By Technique

9. RNA Editing Technologies Market - By Application

10. RNA Editing Technologies Market- By Geography

11. Key Vendor Analysis- RNA Editing Technologies Industry

12. 360 Degree Analyst View

13. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â